Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $8.6 million.

  • Compass Therapeutics' Share-based Compensation fell 43.68% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 10.84%. This contributed to the annual value of $8.6 million for FY2024, which is 39.87% up from last year.
  • Compass Therapeutics' Share-based Compensation amounted to $8.6 million in FY2024, which was up 39.87% from $6.1 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Share-based Compensation registered a high of $8.6 million during FY2024, and its lowest value of $4.0 million during FY2020.
  • Its 3-year average for Share-based Compensation is $6.7 million, with a median of $6.1 million in 2023.
  • Data for Compass Therapeutics' Share-based Compensation shows a peak YoY surged of 338.91% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Compass Therapeutics' Share-based Compensation stood at $4.0 million in 2020, then grew by 0.32% to $4.0 million in 2021, then soared by 32.29% to $5.3 million in 2022, then grew by 14.82% to $6.1 million in 2023, then surged by 39.87% to $8.6 million in 2024.